GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $1.90 billion. The enterprise value is $2.00 billion.
| Market Cap | 1.90B |
| Enterprise Value | 2.00B |
Important Dates
The last earnings date was Thursday, February 27, 2025, before market open.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 384.80 million shares outstanding. The number of shares has decreased by -4.42% in one year.
| Current Share Class | 103.93M |
| Shares Outstanding | 384.80M |
| Shares Change (YoY) | -4.42% |
| Shares Change (QoQ) | -1.27% |
| Owned by Insiders (%) | 3.32% |
| Owned by Institutions (%) | 16.51% |
| Float | 87.86M |
Valuation Ratios
The trailing PE ratio is 123.50 and the forward PE ratio is 29.60. GoodRx Holdings's PEG ratio is 1.95.
| PE Ratio | 123.50 |
| Forward PE | 29.60 |
| PS Ratio | 2.41 |
| Forward PS | 2.26 |
| PB Ratio | 2.60 |
| P/TBV Ratio | 13.87 |
| P/FCF Ratio | 10.41 |
| P/OCF Ratio | 10.34 |
| PEG Ratio | 1.95 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.65, with an EV/FCF ratio of 10.93.
| EV / Earnings | 121.78 |
| EV / Sales | 2.52 |
| EV / EBITDA | 12.65 |
| EV / EBIT | 22.60 |
| EV / FCF | 10.93 |
Financial Position
The company has a current ratio of 5.32, with a Debt / Equity ratio of 0.75.
| Current Ratio | 5.32 |
| Quick Ratio | 4.80 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 3.28 |
| Debt / FCF | 2.97 |
| Interest Coverage | 1.67 |
Financial Efficiency
Return on equity (ROE) is 2.21% and return on invested capital (ROIC) is 4.03%.
| Return on Equity (ROE) | 2.21% |
| Return on Assets (ROA) | 3.71% |
| Return on Invested Capital (ROIC) | 4.03% |
| Return on Capital Employed (ROCE) | 6.99% |
| Revenue Per Employee | $1.14M |
| Profits Per Employee | $23,617 |
| Employee Count | 694 |
| Asset Turnover | 0.53 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $15.07 million in taxes.
| Income Tax | 15.07M |
| Effective Tax Rate | 47.90% |
Stock Price Statistics
The stock price has decreased by -38.86% in the last 52 weeks. The beta is 1.26, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -38.86% |
| 50-Day Moving Average | 4.72 |
| 200-Day Moving Average | 6.46 |
| Relative Strength Index (RSI) | 53.03 |
| Average Volume (20 Days) | 1,711,764 |
Short Selling Information
The latest short interest is 6.81 million, so 1.77% of the outstanding shares have been sold short.
| Short Interest | 6.81M |
| Short Previous Month | 6.68M |
| Short % of Shares Out | 1.77% |
| Short % of Float | 7.75% |
| Short Ratio (days to cover) | 7.24 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $792.32 million and earned $16.39 million in profits. Earnings per share was $0.04.
| Revenue | 792.32M |
| Gross Profit | 743.84M |
| Operating Income | 88.31M |
| Pretax Income | -59.30M |
| Net Income | 16.39M |
| EBITDA | 157.84M |
| EBIT | 88.31M |
| Earnings Per Share (EPS) | $0.04 |
Balance Sheet
The company has $448.35 million in cash and $543.39 million in debt, giving a net cash position of -$95.04 million or -$0.25 per share.
| Cash & Cash Equivalents | 448.35M |
| Total Debt | 543.39M |
| Net Cash | -95.04M |
| Net Cash Per Share | -$0.25 |
| Equity (Book Value) | 724.66M |
| Book Value Per Share | 1.90 |
| Working Capital | 535.35M |
Cash Flow
In the last 12 months, operating cash flow was $183.89 million and capital expenditures -$1.24 million, giving a free cash flow of $182.65 million.
| Operating Cash Flow | 183.89M |
| Capital Expenditures | -1.24M |
| Free Cash Flow | 182.65M |
| FCF Per Share | $0.47 |
Margins
Gross margin is 93.88%, with operating and profit margins of 11.15% and 2.07%.
| Gross Margin | 93.88% |
| Operating Margin | 11.15% |
| Pretax Margin | 3.97% |
| Profit Margin | 2.07% |
| EBITDA Margin | 19.92% |
| EBIT Margin | 11.15% |
| FCF Margin | 23.05% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.42% |
| Shareholder Yield | 4.42% |
| Earnings Yield | 0.86% |
| FCF Yield | 9.61% |
Analyst Forecast
The average price target for GoodRx Holdings is $8.75, which is 77.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.75 |
| Price Target Difference | 77.13% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 7.13% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 2.17 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 7 |